A retrospective analytical study of treatment outcomes among multi drug resistant tuberculosis patients

Published

2021-12-31

DOI:

https://doi.org/10.47203/IJCH.2021.v33i04.019

Keywords:

Retrospective, Multi Drug Resistant, Tuberculosis, RNTCP, NTEP, Treatment Outcome, EDR

Dimensions Badge

Issue

Section

Original Article

Authors

  • Sayed Shakita Fatima King George’s Medical University, Lucknow, Uttar Pradesh https://orcid.org/0000-0001-7257-8002
  • S Kumar King George’s Medical University, Lucknow, Uttar Pradesh
  • Ajay Kumar Verma King George’s Medical University, Lucknow, Uttar Pradesh
  • Suryakant King George’s Medical University, Lucknow, Uttar Pradesh
  • Amod Kumar Sachan King George’s Medical University, Lucknow, Uttar Pradesh
  • Rakesh Kumar Dixit King George’s Medical University, Lucknow, Uttar Pradesh https://orcid.org/0000-0002-6037-0383

Abstract

Background: India is amongst one of the high multidrug resistant tuberculosis (MDR-TB) burden countries globally with a huge contribution given by the state of Uttar Pradesh. Programmatic Management of Drug Resistant Tuberculosis, initiated in 2007 has taken over the disorganized and unsupervised treatment practice in India. However, regular scrutiny is required which points out both its success and failure. Aim & Objective: This study was conducted to evaluate final treatment outcomes among MDR-TB patients on standard Category IV regimen Settings and Design: Retrospective analysis was done using secondary data from medical records of all patients. Methods and Material: Data of all MDR-TB patients registered under RNTCP at King George’s Medical University, Lucknow from 2013 to 2016 was collected. Demographic details along with pre-defined treatment outcomes were recorded (cured, treatment completed, death, treatment failure, treatment default and transfer to higher centre). Statistical analysis used: Descriptive statistics using numbers and percentage. Results: The records of 3580 MDR tuberculosis patients registered at drug resistant tuberculosis centre in King George’s Medical University from January 2013 to December 2016 were included which consisted of 67%males and 33%female. Mean age of presentation was 31.17 years (95% CI 30.75-31.59). Mean weight of patients was 40.16 kg (95% CI 39.89-40.43). Year wise distribution of registered cases from 2013 to 2016 was 611, 799, 984 and 1186 patients respectively. Amongst 3580 patients, 30.39% were declared cured, 25.50% completed treatment, 21.39% died, 0.84% showed treatment failure, 12.54% were defaulters, 2.35% were transferred out to higher centre, 6.5% were shifted to regimen for Extensive drug resistant (EDR) TB, 0.16% patients needed to stop treatment due to ADR and 0.33% patient were still on treatment. Conclusion: The treatment success rate of MDR?TB patients is still low. Measures to improve treatment adherence as in National tuberculosis elimination programme (NTEP) attempts to further improve the success rate.

How to Cite

1.
Fatima SS, Kumar S, Verma AK, Suryakant, Sachan AK, Dixit RK. A retrospective analytical study of treatment outcomes among multi drug resistant tuberculosis patients. Indian J Community Health [Internet]. 2021 Dec. 31 [cited 2022 Aug. 19];33(4):652-7. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/2120

Downloads

Download data is not yet available.

References

World Health Organization. Global tuberculosis report 2020. Geneva: WHO; 2020. p34.

Basil A, Ahmad N, Khan AH, Javaid A, Syed Sulaiman SA, Afridi AK et al. Predictors of two months and the conversion in the multi drug resistant tuberculosis: Findings from a retrospective cohort study. PLoS One. 2014; 9(4):e93206.

Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J PharmacolPharmacother. 2014; 5(2):145-9.

World Health Organization. Global tuberculosis report: Geneva: WHO; 2017:17.

Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. India Tb Report 2020. New Delhi, India. 2020:292.

Guideline for PMDT in India 2017?: Central TB Division. Available at: https://tbcindia.gov.in/index1.php?lang=1& level=2&sublinkid =4780&li =3306. Accessed on 25/12/2021.

World Health Organization. Global tuberculosis report 2016. Geneva: WHO; 2016.

World Health Organization. Global tuberculosis report: Geneva: WHO; 2019:3

Gupta N, Jorwal P. Treatment outcomes associated with multidrug-resistant tuberculosis. J Glob Infect Dis.2018; 10(3):125–8.

Agarwalla, Bhattacharya S, Dey A, Kar S, Chaudhuri AD. Study of outcome of management of MDR-TB cases under programmatic condition in India. J Dr NTR Univ Heal Sci. 2019;8(1):1.

Janmeja AK, Aggarwal D, Dhillon R. Analysis of treatment outcome in multi-drug resistant tuberculosis patients treated under programmatic conditions. Int J Res Med Sci. 2017; 5(6):2401.

Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017; 6(1):7.

Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic. Available at: https://www.who.int/news/item/14-10-2021-tuberculosis-deaths-rise-for-the-first-time-in-more-than-a-decade-due-to-the-covid-19-pandemic. Accessed on 25/12/2021.

Most read articles by the same author(s)